Objective: We hypothesized that a dietary combination of soy with either a probiotic (yoghurt) or a prebiotic (resistant starch) would result in enhanced lipid-lowering effects compared with a control soy diet, possibly via improvements in isoflavone bioavailability. Subjects: Mildly hypercholesterolaemic subjects (men and post-menopausal women) older than 45 years were recruited via the local media. Thirty-six subjects commenced the study; five withdrew. Results: Soy þ probiotic significantly decreased total cholesterol (4.772.0%; P ¼ 0.038) and soy þ prebiotic significantly decreased total and low-density lipoprotein cholesterol (5.571.6%; P ¼ 0.003 and 7.372.2%; P ¼ 0.005, respectively). The bioavailabilities of daidzein, genistein or equol were not affected by probiotic or prebiotic consumption or associated with lipid changes. Conclusion: Dietary combination of soy with either a probiotic or a prebiotic resulted in significant lipid lowering, not related to isoflavone bioavailability.
Introduction
Since publication of Anderson et al. (1995) meta-analysis that reported significant lipid reductions from soy protein intake, much research has been conducted in an attempt to elucidate the specific roles of isoflavones and soy protein in this hypocholesterolaemic effect. A more recent metaanalysis was inconclusive (Yeung and Yu, 2003) and discrepancies remain in relation to the lipid-lowering effects of these soy constituents (Lichtenstein, 1998) . Isoflavone supplements alone generally do not reduce lipids (Nestel et al., 1997; Hodgson et al., 1998) ; however, in combination with soy protein, appear necessary and result in dosedependent lipid lowering (Crouse et al., 1999; Merz-Demlow et al., 2000; Wangen et al., 2001) . Thus, for lipid improvements, the soy protein matrix containing isoflavones and intact soy protein appears to be more beneficial than either component alone (Potter, 1998; Steinberg et al., 2003) .
Following soy intake, the resulting plasma and urinary concentrations of isoflavones and their metabolites vary widely between individuals (Winter and Bokkenheuser, 1987; Rowland et al., 1999) . Gut microflora plays an essential role in isoflavone bioavailability because of the necessity of bacterial enzymes for isoflavone absorption and metabolism (Winter and Bokkenheuser, 1987; Adlercreutz, 1998; Rowland et al., 1999) . If isoflavones are necessary for the hypocholesterolaemic effect of soy, differences between individuals in gut microflora and isoflavone bioavailability may contribute to the variable lipid responses observed.
Adult gastrointestinal microfloral composition is relatively stable; however, diet can substantially modify the metabolic activity of certain bacterial populations (Hentges, 1980; Parodi, 1999) . Of human gut microflora, lactobacilli and bifidobacteria are exclusively beneficial (Gibson, 1998) and thus termed 'probiotic bacteria ' (O'Sullivan, 2001 ). These bacteria have high b-glucosidase activity (Gibson, 1998; O'Sullivan, 2001; Turner et al., 2003) , an enzyme necessary for the initial hydrolysis of the soy isoflavone glucosides and consequent absorption of the bioactive aglycones (Turner et al., 2003) . These probiotic bacteria can be introduced to the gastrointestinal tract as live cultures contained in food matrices, such as yoghurt (Cummings et al., 1997) or alternatively, prebiotic dietary components can selectively stimulate the growth and/or activity of specific probiotic bacteria already resident in the gut (Gibson, 1999) . Resistant starch is a prebiotic carbohydrate and in the large intestine is specifically fermented by bifidobacteria (Brown et al., 1999) , stimulating its growth and increasing b-glucosidase activity (Silvi et al., 1999) .
It is well established that gut microfloral balance affects cholesterol levels (Jenkins et al., 1999) and lipid reductions have been reported with both probiotic intake (AgerholmLarsen et al., 2000a) and prebiotic consumption (Taylor and Williams, 1998; Topping and Clifton, 2001 ). Thus, intake of Lactobacillus and Bifidobacterium or prebiotics that selectively stimulate their growth in the gastrointestinal tract may positively affect both isoflavone and lipid metabolism. We hypothesized that intake of probiotic cultures or a prebiotic dietary component would alter soy isoflavone bioavailability and produce synergistic effects in relation to lipid lowering. This study aimed to compare the lipid effects of soy intake with those of a dietary combination of soy with either a probiotic yoghurt or a prebiotic (resistant starch-enriched bread) and also to determine whether any lipid effects observed were related to changes in isoflavone bioavailability or metabolism.
Subjects and methods

Subjects
Male and female subjects of at least 45 years and good general health were recruited via the local media. Inclusion criteria were mild hypercholesterolaemia (total cholesterol 45.5 mmol l À1 and low-density lipoprotein (LDL) cholesterol 43.0 mmol l
À1
) and for women to have been post-menopausal for more than 12 months. Exclusion criteria included elevated triglycerides (45 mmol l À1 ), BMI o20 or 435, the use of hormone-replacement therapy in the previous 6 months, the use of cholesterol-lowering medication, antibiotics or probiotic supplements in the previous 2 months, alcohol intake (42 standard drinks per day) and cigarette smoking.
Study design
The study consisted of two separate cohorts for comparison of each of probiotic and prebiotic treatments with a corresponding control (Figure 1 ). For each cohort, a randomized crossover design was used, with every subject acting as their own control. Initially, a general health questionnaire was administered via telephone. Eligible subjects were instructed, and routinely reminded, to maintain their usual diet and level of physical activity throughout the study. After a 2-week wash-in period during which soy foods, probiotics and prebiotics were excluded from the diet, subjects commenced the study, which involved two 5-week dietary periods separated by a 4-week washout. All subjects consumed soy milk and soy cereal daily during both dietary periods plus probiotic or prebiotic foods during the corresponding treatments and received advice from a dietician on how to substitute these foods into their usual diets so as to minimize changes in their macronutrient and caloric intake. A test soy meal was consumed prior to and at the end of both 5-week dietary periods to determine the effects on isoflavone bioavailability following a single, controlled soy intake. Subjects were allocated to one of four groups (Pro-1, Pro-2, Pre-1 or Pre-2), which determined the intervention (probiotic or prebiotic) and the order of crossover (Figure 1 ). The control and active dietary treatments for the probiotic cohort were soy þ control yoghurt (S þ YC) and soy þ probiotic yoghurt (S þ YP), respectively, and for the prebiotic cohort were soy control (SC) and soy þ resistant starch bread (S þ RS), respectively. To assist with compliance, subjects with a preference for either yoghurt or bread were allocated accordingly; otherwise, allocation to the probiotic or prebiotic intervention was random as was the order of the crossover.
For each test meal and daily during both 5-week dietary periods, all subjects consumed 250 ml soy milk (So Natural, UHT Calciforte, Taren Point, New South Wales, Australia) and 45 g soy cereal (Specialty Cereals, Mt Kuring-gai, New South Wales, Australia), providing a total of 38 mg daidzein and 68 mg genistein and 4.5 mg glycitein (aglycone equivalents). Sufficient quantities of each food were provided to subjects at the beginning of each dietary period; soy milk was given in 1 l cartons, from which subjects were asked to measure and consume 250 ml daily and soy cereal was prepackaged as individual 45 g serves.
For the probiotic intervention, subjects consumed 100 ml yoghurt per day (Vaalia, Pauls Dairy, Brisbane, Qld, Australia) either with (probiotic) or without (control) live bacterial cultures. The probiotic yoghurt contained 10 8 colony forming units (CFU) of each of Lactobacillus acidophilus, Bifidobacterium bifidus and Lactobacillus GG per 100 g daily serve. There were no flavour or texture differences between the two yoghurts, both were vanilla flavoured of 'low' fat (1.4% content) and the containers were unmarked except for a numerical code. Individual 100 ml serves of yoghurt were provided fresh to subjects every 3 weeks and stored under refrigeration. For the prebiotic intervention, bread was baked using 70% resistant starch flour (Penford Australia Ltd, Sydney, New South Wales, Australia) by a local bakery (K & M Bakery, Woonona, New South Wales, Australia) to provide approximately 4 g resistant starch per slice. Bread was baked every 2-3 weeks and either delivered to subjects on the day of baking or frozen in the clinic area for pick-up. Subjects consumed 4-5 slices of bread per day (to provide a total of 16-20 g RS).
At the start of weeks 0, 5, 9 and 14 ( Figure 1 ), subjects attended the clinic at the University of Wollongong on two consecutive days. On the first morning, height and weight were recorded, a fasted blood sample was taken, then a test soy meal of 250 ml soy milk and 45 g soy cereal was consumed. After this, a food frequency questionnaire was administered and subjects commenced a 24 h urine collection. Subjects did not consume any other soy foods, probiotics or prebiotics for 48 h post-meal but otherwise continued their usual activities and diet. Blood was again collected 8 and 24 h after the test meal and a second 24 h urine sample was collected between 24 and 48 h post-meal. Urine samples were collected in 2.5 l collection bottles containing 1 g ascorbic acid and after completion, the total volume of each 24 h collection was recorded and duplicate 5 ml aliquots were stored at À80 1C until analysis. Blood was collected by a registered nurse into ethylenediaminetetraacetic acid tubes (Sarstedt) which were inverted and then placed on ice until they were centrifuged at 4 1C for 10 min at 2100 g. Plasma was harvested and stored in duplicate aliquots at À80 1C until analysis.
Isoflavone analysis
Extraction of isoflavones from plasma and urine was based on the methods reported by Gamache and Acworth (1998) with modifications and optimizations (Larkin, 2005) . All reagents and standards were from Sigma-Aldrich (Castle Hill, New South Wales, Australia) and solvents were high performance liquid chromatography grade (Crown Scientific, Moorebank, New South Wales, Australia). In the purified, extracted samples, isoflavones were separated via reversephase high performance liquid chromatography (Shimadzu auto-injector) with an isocratic mobile phase of 50 mM sodium acetate buffer pH 4.8 with acetic acid/methanol (45:55) and quantified by electrochemical detection at þ 750 mV (VT-03, Antec Leyden) using optimized methods developed in our laboratory (Larkin, 2005) . Mixed standards of genistein (Sigma, G6649), daidzein (Sigma, D7802), equol (Sigma, 45405), O-desmethylangolensin (ODMA; Plantech, UK) at concentrations between 0.2 and 2 mM for plasma, and 0.2 and 4 mM for urine, were included in each high performance liquid chromatography run at least in triplicate. Limits of quantification for plasma and urine, respectively were 5 ng ml À1 and 1 mg ml
À1
, for daidzein and genistein, 15 ng ml À1 and 2 mg ml
, for equol 60 ng ml À1 and for ODMA 6 mg ml À1 (Larkin, 2005) . Within-run coefficients of variation for peak area of standards (% standard deviation/ mean) were less than 5% for daidzein and genistein, less than 10% for equol and less than 20% for ODMA. Recoveries were greater than 70% and calculated values were not adjusted for recoveries.
Lipid analysis
Total cholesterol and triglycerides were measured in whole plasma. High-density lipoprotein (HDL) was isolated by precipitation using the dextran sulphate/magnesium chloride method (Warnick et al., 1982) . Briefly, plasma samples were mixed with a solution of dextran sulphate and magnesium chloride, centrifuged and then the clear supernatant was aliquoted for HDL measurement. Total cholesterol, HDL cholesterol and triglycerides were determined using a commercially available enzymatic colorimetric test kit (Roche Diagnostics, Castle Hill, New South Wales, Australia) and analysed in triplicate using an auto-analyser (Cobas Mira Plus; Roche Diagnostics). Plasma LDL cholesterol was calculated using the Friedewald et al.'s (1972) calculation. The coefficient of variation was 0.8% for cholesterol and 1.5% for triglycerides.
Ethics
Ethics approval for this study was granted by the University of Wollongong Human Research Ethics Committee (Ethics number 02/248) and all procedures complied with National Health and Medical Research Council standards required in Australia. Written, informed consent was obtained from all subjects prior to commencement of the study.
Statistics
Initially, the normality of data sets was examined (SPSS 11.5, SPSS Inc. Chicago, IL, USA). Analysis of variance (ANOVA) with repeated measures and Bonferroni post hoc analysis (SPSS 11.5, SPSS Inc.) were used and reported with F values, degrees of freedom (d.f.; hypothesis d.f., error d.f.) and P-values (for between groups analyses or Bonferroni post hoc). Factors for two-way ANOVA were always treatment and week. Student's t-tests were two-tailed (Microsoft Excel/SPSS 11.5, SPSS Inc.) and paired, as only within-subject comparisons were made. All values are reported as mean7s.e.m. To check for an intervention order effect, two-way ANOVA with repeated measures (factors of treatment and week) and between groups analysis were performed. To determine the effects of the dietary periods on plasma and urinary isoflavone concentrations, three-way ANOVA with repeated measures (factors of treatment, week and sample time) were conducted, but reported in detail elsewhere (Larkin et al., submitted manuscript) . Any relation between plasma or urinary isoflavone concentrations or changes and lipid levels or changes, were tested by bivariate correlations with Pearson's correlation coefficient (SPSS 11.5, SPSS Inc.). For determination of any overall effects of the 14-week period, the data of all subjects were included in one-way ANOVA with repeated measures and Bonferroni post hoc analysis.
Results
Thirty-six subjects (15 females and 21 males) commenced the study, however 5 people withdrew for a variety of personal reasons; consequently, 31 subjects (12 females and 19 males) completed the study. All females were postmenopausal for at least 12 months, 10 had never used hormone-replacement therapy and the other 2 had not in the previous 6 months. Distribution of subjects and mean ages for the four study groups are presented in Table 1 . Subject age was not significantly different between the groups (F ¼ 1.020, P ¼ 0.399, one-way ANOVA). There were no significant changes in body weight during the study and reported food intake did not differ significantly between the two dietary periods and the washout (data not shown). Mean intake of daidzein and genistein for each test soy meal and for the daily soy intake during dietary periods was 0.4870.01 and 0.8470.02 mg kg À1 body mass, respectively.
Mean lipid levels (range in parentheses) for all subjects at baseline were TCh: 6.6570.17 mmol l À1 (5.55-9.19), HDL: There were no significant differences between the two probiotic groups for lipid changes (TCh: F ¼ 1.930, P ¼ 0.186; HDL: F ¼ 0.588, P ¼ 0.456; LDL: F ¼ 1.115, P ¼ 0.309; TG: F ¼ 2.684, P ¼ 0.125, two-way ANOVA with repeated measures), thus groups were combined for further analysis. However, there were significant differences between the two prebiotic groups for total and LDL cholesterol (TCh: F ¼ 5.534, P ¼ 0.035; HDL: F ¼ 0.015, P ¼ 0.905; LDL: F ¼ 5.224, P ¼ 0.040; TG: F ¼ 0.277, P ¼ 0.608, two-way ANOVA with repeated measures). Pre-1 showed a significant increase in LDL (Po0.01) and a trend for an increase in TCh (P ¼ 0.069) during the washout period (weeks 5-9), whereas Pre-2 had a mean decrease in both of these measure over the same time (Table 2) . Interestingly, this latter group followed the S þ RS dietary period first (Figure 1) , which may indicate an order effect. The prebiotic groups were initially analysed separately, then combined for further analyses since these significant differences were not effective for the actual dietary treatments.
Total cholesterol was significantly reduced with 5 weeks of S þ YP and S þ RS treatments and LDL cholesterol was significantly reduced after the S þ RS and SC dietary periods (Table 3, Student's paired t-tests, comparing weeks 0 and 5). There were no significant differences between either of the probiotic or prebiotic treatments and their respective controls for any of the four lipid measures (two-way ANOVA with repeated measures). There was an overall temporal effect for both TCh and LDL (F 3,27 ¼ 7.055, P ¼ 0.001 and F 3,27 ¼ 5.027, P ¼ 0.007, respectively, one-way ANOVA with repeated measures), but none for either of HDL or TG (F 3,27 ¼ 1.900 P ¼ 0. 531 and F 3,27 ¼ 2.182, P ¼ 0.133, respectively, one-way ANOVA with repeated measures). TCh was significantly reduced between weeks 0 and 14 (P ¼ 0.009) and weeks 9 and 14 (P ¼ 0.026) and LDL was significantly reduced between weeks 0 and 5, weeks 0 and 14, and weeks 9 Abbreviations: n ¼ number of subjects; S, soy; S þ YC, soy þ control yoghurt; S þ YP, soy þ probiotic yoghurt; SC, soy control; S þ RS, soy þ resistant starch; RS, resistant starch bread. Pro-1 and Pro-2: crossover groups of probiotic cohort; Pre-1 and Pre-2: crossover groups of prebiotic cohort. Mean7s.e.m.
and 14 (P ¼ 0.021, P ¼ 0.049 and P ¼ 0.035, respectively). While there was a trend for a mean increase in TG with both soy control dietary periods, there were no increases with S þ YP and S þ RS (Table 3) . At the end of each dietary period, plasma and urinary concentrations of daidzein and genistein were highly variable between subjects (Table 4 ). There were no significant correlations between lipid levels and plasma or urinary daidzein or genistein concentrations and during the same dietary period (data not shown). Equol occurrence in plasma and urine also showed high inter-individual variability with three distinctly different patterns of equol production evident among subjects. Throughout the study, 12 subjects consistently had plasma and/or urine equol, 10 subjects had equol in a single plasma or urine sample and 9 subjects never produced equol. There were no significant differences between these subgroups in baseline lipids, nor any of the lipid effects of any of the dietary periods (data not shown).
Discussion
In this study, 5 weeks of soy plus probiotic intake significantly decreased total cholesterol by 4.772.0% (À0.3270.14 mmol l
À1
). This is similar to other studies of moderately and hypercholesterolaemic subjects, reporting significant reductions in total and LDL cholesterol of up to 6 and 10%, respectively with intake of probiotic milk products (Agerbaek et al., 1995; Richelson et al., 1996; Schaafsma et al., 1998; Agerholm-Larsen et al., 2000b; Xiao et al., 2003) , as well as the results of a small meta-analysis (Agerholm-Larsen et al., 2000a). Greany et al. (2004) also examined the effects of combined soy and probiotic intake on lipids; however in their study, intake of soy protein isolate over 6 weeks significantly reduced total and LDL cholesterol in hypercholesterolaemic subjects by 5 and 6%, respectively, while concurrent intake of 10 9 CFU L. acidophilus and Bifidobacterium bifidum had no additional benefit. It is possible that the significant hypocholesterolaemic effect of soy protein isolate was maximal and that combination of soy and probiotic showed no further improvement. In vitro, probiotic bacteria including L. acidophilus and B. bifidus can assimilate cholesterol (Gomes and Malcata, 1999) and deconjugate bile salts (Pereira and Gibson, 2002) . Probiotic bacteria may also assimilate dietary cholesterol, reducing it's absorption (Pereira and Gibson, 2002; Xiao et al., 2003) and increase bile acid excretion, further reducing serum cholesterol as it is converted to replace the excreted bile acids (Sanders, 2000; Pereira and Gibson, 2002) . However, these effects are dependent on the ingested bacterial strains colonizing the small intestine where most cholesterol absorption takes place (Pereira and Gibson, 2002) . Our finding that 5 weeks intake of soy plus resistant starch significantly reduced total and LDL cholesterol by 5.571.6% (À0.3670.10 mmol l À1 ) and 7.372.2% (À0.3270.10 mmol l À1 ), respectively, is of particularly interest. There are few human studies in this area; however, similar findings indicate a potential benefit of combining prebiotic and soy intake. Total and LDL-cholesterol levels were also significantly reduced after daily intake of soy protein and 18 g of resistant starch for 3 weeks (Muir et al., 1998) and 33 g soy protein and 8 g soluble fibre for 1 month (Jenkins et al., 1999) . Furthermore, 2 weeks daily intake of 21.5 g high amylose corn starch, similar to resistant starch, was associated with lower total and LDL cholesterol (Jenkins et al., 1999 ) and animal studies demonstrate significantly reduced lipid levels with prebiotic intake (Taylor and Williams, 1998) . Prebiotic intake directly affects the carbohydrate fermentation activity of the microflora, which itself has also been suggested to be related to lipid profiles (Jenkins et al., 1999) . Production of propionate may decrease serum cholesterol (Jenkins et al., 1999) and this is one of the major short chain fatty acid products of intestinal fermentation of resistant starch (Brown et al., 1998; Rowland, 1999; Topping and Clifton, 2001 ).
In the current study, total cholesterol remained lower 4 weeks after soy plus resistant starch intake ceased. When soy plus resistant starch was consumed first, there was a mean reduction in total cholesterol (0.1870.07 mmol l
) during this 5-week dietary period and then a further mean reduction (0.1570.10 mmol l
) during the 4-week washout. In contrast, no other groups showed a mean decrease in total cholesterol during the washout period, suggesting a longlasting effect of resistant starch intake in relation to lipid lowering. The convenient incorporation of resistant starch into bread (Brown, 1996; Hoebler et al., 1999) allows for potential functional food developments with soy in relation to hypercholesterolaemia.
The only significant effect of the soy control diet was a reduction in LDL of 4.172.1% (À0.2170.09 mmol l À1 ) in the prebiotic cohort. During all dietary periods, the soy foods provided 38 mg daidzein, 68 mg genistein, 4.5 mg glycitein (aglycone equivalents) and 10 g soy protein per day. The lack of significant lipid reductions may support the suggestion that a minimum amount of soy protein is necessary for lipidlowering effects. The 1999 health claim for the hypocholesterolaemic effect of soy protein (FDA, USA) was based on a daily intake of 25 g soy protein, and three meta-analyses reporting reductions in total cholesterol of approximately 4% or more were based on soy protein intakes of between 22.5 and 47 g per day (Anderson et al., 1995; Weggemans and Trautwein, 2003; Harland and Carr, 2004) . The significant lipid-lowering effects of the combination of soy with a probiotic or a prebiotic were not associated with changes in isoflavone bioavailability or equol production. Results of probiotic and prebiotic effects on isoflavone bioavailability are reported elsewhere (TA Larkin, submitted manuscript).
The lipid-lowering effects of soy intake may depend on initial cholesterol levels. In the original meta-analysis (Anderson et al., 1995) , only subjects with total cholesterol greater than 6.7 mmol l À1 achieved significant lipid reductions with soy intake. In the present study, 10 subjects had total cholesterol greater than 6.7 mmol l À1 (mean 7.6370.30 mmol l
) at the beginning of their control soy dietary period and this significantly decreased during the control soy period by 0.3270.13 mmol l À1 (À4.171.8%; P ¼ 0.04, Student's paired t-test). Thus, similar to Anderson's meta-analysis, soy intake resulted in significant lipid lowering in subjects with baseline total cholesterol greater than 6.7 mmol l À1 . In the current study, none of the treatments significantly affected triglyceride or HDL-cholesterol levels, consistent with literature (Agerbaek et al., 1995; Richelson et al., 1996; Schaafsma et al., 1998) . There was also an overall temporal effect, of significantly reduced total and LDL cholesterol over the 14-week study duration. Considering the trend towards a reduction in total and LDL cholesterol with the soy control and the lack of significant difference between the treatment and control for both cohorts, the significant effects of combination with the probiotic or prebiotic appear to be additive rather than solely attributable to either of these latter components. However, subject numbers were small and as the study design did not include control probiotic or prebiotic treatments, the proportional effect of each component cannot be assessed. Further examination of the effects reported here, particularly long-term studies, would be beneficial, as would inclusion of microbial analyses to determine whether these effects are related to specific changes in gut microflora activity. Overall, our results suggest limited lipid-lowering effects of soy consumption and potential synergistic hypocholesterolaemic action between soy and probiotic bacteria.
